Edwards Lifesciences (EW) Cash from Operations (2009 - 2026)

Edwards Lifesciences' Cash from Operations history runs 18 years deep, the most recent figure standing at 43800000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 84.38% year-over-year to 43800000.0 in Q1 2026; TTM through Mar 2026 was 1358600000.0, a 55.06% increase from a year earlier, with the FY2025 full-year figure at 1595200000.0, up 194.15% from the prior year.
• Cash from Operations slipped to 43800000.0 in Q1 2026 per EW's latest filing, from 450900000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 573700000.0 in Q3 2025 and bottomed at 127500000.0 in Q4 2024.
• The 5-year median for Cash from Operations is 293300000.0 (2022), against an average of 252664705.88.
• Biggest YoY gain for Cash from Operations was 1005.65% in 2024; the steepest drop was 193.34% in 2024.
• Year by year, Cash from Operations stood at 282800000.0 in 2022, then tumbled by 51.7% to 136600000.0 in 2023, then sank by 193.34% to 127500000.0 in 2024, then jumped by 453.65% to 450900000.0 in 2025, then slumped by 90.29% to 43800000.0 in 2026.
• Per Business Quant, the three latest EW Cash from Operations figures stand at 43800000.0 (Q1 2026), 450900000.0 (Q4 2025), and 573700000.0 (Q3 2025).